We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Response of Cancers to BRAF Inhibition Underscores the Importance of Cancer Systems Biology.
- Authors
Stites, Edward C.
- Abstract
The BRAF inhibitor vemurafenib has become an important treatment option for melanoma patients, the majority of whom have a BRAF(V600E) mutation driving their malignancy. However, this same agent does not generally benefit colon cancer patients who have the BRAF(V600E) mutation. Recent work suggests that BRAF(V600E) inhibition by vemurafenib results in decreased negative feedback to the epidermal growth factor receptor (EGFR) pathway and that the different clinical responses are due to differences in the amount of EGFR present in these two cancers. The experimental work that identified the feedback signaling was an elegant mix of functional genomic approaches and focused, hypothesis-driven cellular and molecular biology. The results of these studies suggest that combined treatment of BRAF(V600E)-driven colon cancers with both vemurafenib and EGFR inhibitors is worth clinical evaluation.
- Publication
Science Signaling, 2012, Vol 5, Issue 246, p1
- ISSN
1945-0877
- Publication type
Article
- DOI
10.1126/scisignal.2003354